Prof. Dr Susann Schweiger
Research Group Leader LIR, Director of Institute for Human Genetics University Medical Center of the Johannes Gutenberg-University Mainz, Professor for Human Genetics
Leibniz-Institut für Resilienzforschung gGmbH
Langenbeckstraße 1
55131 Mainz
1970
Research Group Leader, Leibniz Institute for Resilience Research (LIR), Mainz, Germany Professor for Human Genetics, Director of Institute for Human Genetics, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Board certification Human Genetics, Ärztekammer Berlin, Germany
Residency training Human Genetics, Charité University Medicine Berlin, Germany
Registrar: Department of Dermatology, Charité University Medicine Berlin, Germany, Full registration, Ärztekammer Hamburg, Germany
Registrar: Department of Pharmacology, University Hospital FU Berlin, Germany
Registrar: Department of Internal Medicine, University Hospital Hamburg, Germany
Provisional registration, Ärztekammer Hamburg, Germany
Dr. med. (M.D.); Innsbruck Medical School, Austria 10/1993; Graduation; Innsbruck Medical School, Austria
Undergraduate Training; Innsbruck Medical School, Austria
Dr. med. (M.D.); Innsbruck Medical School, Austria 10/1993; Graduation; Innsbruck Medical School, Austria
Research Group Leader at the Leibniz Institute for Resilience Research (LIR), Mainz, Germany
Research Group Leader at the German Resilience Center (DRZ) Mainz, Germany
Professor for Human Genetics, University Medical Center of the Johannes Gutenberg University Mainz, Germany
Director Institute for Human Genetics, University Medical Center of the Johannes Gutenberg University Mainz, Germany
Professor for Molecular Medicine, Ninewells Hospital, Dundee, Scotland, United Kingdom
Academic Lead of the Department for Human Genetics
Deputy Head of the Wellcome Trust Centre for Molecular Medicine
Head of the Centre for Oncology and Molecular Medicine
Lichtenberg Professor for Clinical and Molecular Genetics, Charité University Medicine, Berlin, Germany
M.D.-Ph.D. thesis: Institute of Organic Chemistry and Biochemistry, Freiburg, Germany; “Purification, characterization and crystallization of the membrane protein Maltoporin, the membrane-associated proteins Adrenodoxin Reduktase, and the tissue-plasminogene activator tPA” (supervisor: Georg E. Schulz, University of Freiburg, Germany)
Lichtenberg professorship of the “Volkswagenstiftung”
Research grant of the Max Planck Society
Member of the “Studienstiftung des Deutschen Volkes”
Arnoux I, Willam M, Griesche N, Krummeich J, Watari H, Offermann N, Weber S, Narayan Dey P, Chen C, Monteiro O, Buettner S, Meyer K, Bano D, Radyushkin K, Langston R, Lambert JJ, Wanker E, Methner A, Krauss S, Schweiger S, Stroh A (2018) Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease. eLife 7:e38744. doi: 10.7554/eLife.38744.
>> Link to PubmedSchweiger S, Matthes F, Posey K, Kickstein E, Weber S, Hettich MM, Pfurtscheller S, Ehninger D, Schneider R, Krauß S (2017) Resveratrol induces de-phosphorylation of tau by interfering with the MID1-PP2A complex. Sci Rep 7(1):13753. doi: 10.1038/s41598-017-12974-4.
>> Link to PubmedSchweiger S, Dorn S, Fuchs M, Köhler A, Matthes F, Müller EC, Wanker E, Schneider R, Krauß S (2014) The E3-ubiquitin ligase MID1 catalyzes ubiquitination and cleavage of Fu. J Biol Chem 289(46):31805–17. doi: 10.1074/jbc.M113.541219.
>> Link to PubmedKrauss S, Griesche N, Jastrzebska E, Chen C, Rutschow D, Achmüller C, Dorn S, Boesch SM, Lalowski M, Wanker E, Schneider R, Schweiger S (2013) Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex. Nat Commun 4:1511. doi: 10.1038/ncomms2514.
>> Link to PubmedAranda-Orgilles B, Rutschow D, Zeller R, Karagiannidis AI, Köhler A, Chen C, Wilson T, Krause S, Roepcke S, Lilley D, Schneider R, Schweiger S (2011) Protein phosphatase 2A (PP2A)-specific ubiquitin ligase MID1 is a sequence-dependent regulator of translation efficiency controlling 3-phosphoinositide-dependent protein kinase-1 (PDPK-1). J Biol Chem 286:39945–39957.
>> Link to PubmedLiu E, Knutzen CA, Krauss S, Schweiger S, Chiang GG (2011) Control of mTORC1 signaling by the Opitz syndrome protein MID1. Proc Natl Acad Sci USA 108:8680–8685.
>> Link to PubmedKickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, Köhler A, Glossmann H, Schneider R, Sutherland C, Schweiger S (2010) Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA 107:21830–21835.
>> Link to PubmedKrauß S, Foerster J, Schneider R, Schweiger S (2008) Protein phosphatase 2A and rapamycin regulate the nuclear localization and activity of the transcription factor GLI3. Cancer Res 68(12):4658–4665.
>> Link to PubmedKalscheuer VM, Freude K, Musante L, Jensen LR, Yntema HG, Gécz J, Sefiani A, Hoffmann K, Moser B, Haas S, Gurok U,Haesler S, Aranda B, Nshedjan A, Tzschach A, Hartmann N, Roloff TC, Shoichet S, Hagens O, Tao J, van Bokhoven H, Turner G, Chelly J, Moraine C, Fryns JP, Nuber U, Hoeltzenbein M, Scharff C, Scherthan H, Lenzner S, Hamel BCJ, Schweiger S, Ropers HH (2003) Mutations in the polyglutamine binding protein 1 gene cause X-linked mental retardation. Nat Genet 35(4):313–315.
>> Link to PubmedTrockenbacher A, Suckow V, Foerster J, Winter J, Krauß S, Ropers HH, Schneider R, Schweiger S (2001) MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Nat Genet 29:287–294.
>> Link to Pubmed